US Patent 8,534,281: Claim Scope, Patent Landscape, Exclusivity and Inhaler Design-Around Analysis
US Patent 8,534,281 protects a specific airflow manifold architecture for multi-blister dry-powder inhalers. Its core limitation is a single chimney inlet feeding multiple paired chimney exits and chamber inlets, with bleed holes diverting most airflow directly into the chamber to disrupt and condition the powder-carrying streams. The patent does not broadly claim inhalable medicaments, blister packs, or inhalers generally. Infringement depends on the accused device having the claimed manifold geometry and airflow relationships.
The patent is most relevant to inhalers that simultaneously or sequentially present multiple opened blister pockets to a common mouthpiece, particularly devices using separate blister strips for combination therapies such as a bronchodilator and corticosteroid.
What does US Patent 8,534,281 cover?
The patent covers three related product levels:
| Claim group |
Protected subject matter |
Principal claims |
| Manifold |
Airflow manifold with chimney, chamber, paired exits and inlets, and bleed holes |
1-28, 52-28, 52-28, 57-61 |
| Manifold-mouthpiece subassembly |
Manifold fitted to a mouthpiece, including releasable and snap-fit configurations |
29-31 |
| Medicament dispenser |
Device using the manifold with blister packs, indexing and blister-opening mechanisms |
32-51 |
The broadest independent claim is claim 1. Claims 29 and 32 extend protection to assemblies and complete dispenser devices, but both incorporate the limitations of claim 1.
The patent therefore has a layered claim structure. A competitor may avoid claim 32 by omitting the claimed blister-pack mechanism, but still face claim 1 if its standalone manifold satisfies the claimed airflow architecture.
What are the key limitations of independent claim 1?
Claim 1 requires all of the following:
- A manifold for a medicament dispenser.
- A body defining a chimney.
- The chimney has only one chimney inlet.
- The chimney has multiple chimney exits.
- The body also defines a chamber.
- The chamber has multiple chamber inlets and a chamber exit.
- Chimney exits and chamber inlets form multiple pairings.
- Each pairing is associated with a different opened blister pocket.
- The chimney exit and chamber inlet in each pairing are side-by-side.
- Air moves from each chimney exit through the associated blister pocket into the paired chamber inlet.
- One or more bleed holes connect the chimney and chamber.
- Bleed airflow disruptively impacts the airflow carrying entrained powder.
The claim is narrower than a general claim to a manifold having multiple powder inlets. It requires a particular fluidic architecture in which the incoming air is divided between:
- an entraining airflow passing through the opened blister pockets; and
- a bleed airflow entering the chamber through dedicated bleed holes.
The claim also requires the bleed airflow to disrupt the powder-bearing airflow. A device with passive leakage that does not produce the claimed disruptive interaction may present a claim-construction and infringement issue.
How do the dependent claims narrow the patent scope?
The dependent claims impose numerical, geometric, material and product-level limitations.
Airflow allocation and resistance
| Claim |
Limitation |
| 2 |
3%-50% of total airflow passes through the chimney exits; 50%-97% passes through bleed holes |
| 3 |
5%-25% entraining airflow; 75%-95% bleed airflow |
| 4 |
1-5 kPa airflow resistance at 60 liters/minute |
| 24 |
Bleed airflow is greater than entraining airflow |
Claims 2, 3 and 24 indicate that the invention is directed toward a relatively high bypass or bleed-flow configuration. The majority of inhaled air can bypass the blister pockets and enter the chamber directly. This reduces the risk that the powder-carrying stream will remain concentrated or impact the chamber wall in a manner that causes excessive deposition.
Claims 2 and 3 are quantitative limitations. They may be important in litigation because infringement would depend on testing or validated computational-fluid-dynamics analysis at the relevant operating condition.
Chimney and chamber geometry
| Claims |
Protected geometry |
| 5, 52 |
Essentially circular chimney exit, with a diameter of 1-7 mm |
| 6-7 |
Cross-piece across a chimney exit, including a cruciform cross-piece |
| 8 |
Chimney and chamber positioned side-by-side |
| 9 |
Chimney and chamber positioned one above the other |
| 10-11 |
Chimney and chamber share a wall containing the bleed holes |
| 22 |
Chimney and chamber are generally perpendicular |
| 57 |
Chamber has only one chamber exit |
| 58-59 |
Curved walls receive opened blister pockets and define paired exits and inlets |
The claims cover several relative orientations. A competitor cannot necessarily avoid the patent merely by rotating the chimney and chamber from a side-by-side arrangement to a stacked or perpendicular arrangement, because claims 8, 9 and 22 expressly address those alternatives.
Claims 58 and 59 are directed to a more specific pocket-receiving configuration. They are relevant to devices in which curved manifold walls closely conform to opened blister pockets.
Bleed-hole structure
| Claims |
Limitation |
| 12 |
Total bleed-hole area of 1-35 mm² |
| 13 |
Ovular, circular, D-shaped or elongate-slot profile |
| 14 |
Slot length of 1-20 mm and width of 0.5-3 mm |
| 15 |
Two parallel elongate slots |
| 16 |
Bleed holes spaced from chimney exits |
| 17 |
Spacing is at least 10% of chamber length |
| 18 |
At least one bleed hole directs air toward a chamber wall |
| 53 |
Total bleed-hole area of 10-30 mm² |
| 54 |
Slot length of 3-10 mm and width of 0.7-2 mm |
| 55-56 |
Spacing is at least 20% or 30% of chamber length |
| 60 |
Slots taper toward the chimney exits |
| 61 |
Bleed airflow forms a sheath-like blanket along the chamber boundary |
Claim 61 is technically important. It narrows the bleed-hole geometry to a tapered configuration that causes part of the bleed airflow to travel along the chamber boundary. The claim may be difficult to establish without physical testing because the sheath-like airflow behavior is functional rather than purely structural.
Materials and manufacture
Claims 19-21 cover:
- high-density polyethylene;
- fluoropolymer materials;
- PTFE;
- FEP;
- PFA;
- ETFE;
- PVDF;
- chlorinated ethylene tetrafluoroethylene; and
- mixtures of those materials.
Claims 27 and 28 cover a one-piece moulded article. These limitations favor low-cost injection-moulded manifolds and can complicate design-arounds that use separate manifold components.
What airflow problem does the patent address?
The manifold combines two airflow paths:
Single chimney inlet
|
+--> chimney exits --> opened blister pockets --> chamber inlets
|
+--> bleed holes -----------------------------> chamber
|
chamber exit
The entraining airflow passes through the powder-containing blister pockets. The bleed airflow enters downstream and disrupts, dilutes or redirects the powder-laden streams before they reach the mouthpiece.
The specification's technical concept, as reflected in the claims, is not simply to increase total airflow. It is to control the proportion and location of bypass airflow so that:
- powder is extracted from multiple blisters;
- the streams are mixed within a common chamber;
- wall deposition is reduced;
- airflow resistance remains suitable for inhalation; and
- separate medicament components can be delivered through a common mouthpiece.
The claimed architecture is particularly relevant where multiple blister strips are used to deliver separate active ingredients.
What medicament and blister-pack configurations are covered?
Claims 32-51 extend the manifold into a dispenser system.
The device claims cover:
- one or more blister packs;
- plural pockets containing distinct doses;
- elongate strip-form blister packs;
- base sheets with formed recesses;
- peelable lid sheets;
- blister-opening mechanisms;
- indexing mechanisms that present pockets one at a time;
- simultaneous delivery from multiple blister packs;
- a bronchodilator and an anti-inflammatory;
- beta-agonist and corticosteroid combinations; and
- two blister packs containing different medicaments.
The patent does not claim a specific active pharmaceutical ingredient by name. It claims device configurations capable of delivering therapeutic classes and combinations.
The distinction matters for freedom-to-operate analysis. A product containing a beta-agonist and corticosteroid does not infringe merely because of its formulation. The accused product must also use a manifold and dispenser arrangement satisfying the structural and functional limitations.
How strong is the independent claim structure?
Claim 1 has meaningful commercial breadth but substantial technical specificity.
Strengths
- It captures the central manifold architecture rather than a narrow drug formulation.
- It applies to multiple blister-pack arrangements.
- It covers several chimney and chamber orientations through dependent claims.
- It captures both complete inhalers and potentially separately supplied manifold components.
- It includes functional airflow behavior that may reach equivalent structures depending on claim construction.
Limitations
- The claim requires both a chimney and chamber.
- The chimney must have only one inlet and multiple exits.
- The chamber must have multiple inlets and an exit.
- The exits and inlets must form side-by-side pairings.
- The bleed holes must connect the chimney and chamber.
- The bleed airflow must disrupt the powder-transport airflow.
- Claims 2-4 and 12-18 depend on measurable airflow or dimensional parameters.
A conventional single-blister inhaler with one powder inlet is less likely to fall within claim 1 because it may lack plural pairings. A multi-dose inhaler that opens one blister at a time may also avoid claim 1 if it does not use multiple simultaneous blister-pocket pairings, although claim 32 reaches devices suitable for at least one blister pack and must be assessed against the full claim language.
What patent landscape surrounds US Patent 8,534,281?
The relevant landscape has five technical patent clusters.
Multi-blister inhaler architecture
This cluster covers:
- multiple blister strips;
- simultaneous delivery from separate packs;
- common mouthpieces;
- dose indexing;
- blister-pocket presentation;
- strip separation and peel mechanisms.
These patents can create overlapping rights even when a competitor avoids the specific bleed-hole architecture.
Powder entrainment and airflow mixing
This cluster covers:
- high-resistance inhalers;
- turbulence generators;
- bypass channels;
- mixing chambers;
- impact surfaces;
- particle deagglomeration;
- wall-deposition reduction; and
- flow-balancing structures.
US 8,534,281 is strongest where the accused product uses a common chamber with deliberate bleed airflow. Other airflow patents may apply to alternative mixing structures.
Blister-strip opening mechanisms
Claims 35-49 address mechanisms that open and present pockets. Separate patent families commonly protect:
- peelable lid arrangements;
- lengthwise strip separation;
- indexed pocket presentation;
- removable strip portions;
- pocket alignment;
- synchronized opening of multiple strips.
A competitor may avoid the manifold claims but still face patents directed to the blister-opening mechanism.
Combination inhaler products
Claims 43-45 and 50-51 identify combination therapy applications. These claims are device-oriented, while separate patents may protect:
- specific active ingredients;
- particle engineering;
- carrier particles;
- dose ratios;
- capsule or blister formulations;
- treatment methods; and
- fixed-dose combinations.
The patent should not be treated as a composition patent. It does not, on the supplied claims, claim a particular bronchodilator, corticosteroid, salt, polymorph or particle-size distribution.
Materials and manufacturing
Claims 19-21, 27 and 28 create a secondary layer of protection around:
- moulded polymer manifolds;
- low-friction internal surfaces;
- fluoropolymer coatings;
- one-piece articles; and
- injection-moulded geometry.
These claims may be relevant to manufacturing suppliers even where the final inhaler is assembled by a separate company.
What is the Orange Book status of US 8,534,281?
US 8,534,281 is directed to a manifold and medicament dispenser device, not to a named active ingredient or a drug formulation. On the supplied claim set, it would not ordinarily qualify as a standard drug-substance or drug-product patent for Orange Book listing under 21 C.F.R. § 314.53.
The patent may still be commercially relevant to an FDA-approved inhaler through device ownership, licensing, procurement or contractual restrictions. Orange Book listing and enforceability are separate issues. A device patent can create infringement risk even when it is absent from the Orange Book.
An Orange Book search should therefore be performed by:
- approved product;
- NDA holder;
- active ingredient;
- inhaler device name; and
- patent family member.
The supplied claim set alone does not establish a particular Orange Book listing.
When does US Patent 8,534,281 lose exclusivity?
The patent issued on September 17, 2013. US patent expiration is generally calculated from the earliest effective nonprovisional or international filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers and other prosecution events. The grant date does not determine the expiration date.[1]
A reliable expiration analysis requires the patent's continuity data and USPTO Patent Center term record. The claims supplied do not contain that information. The patent's enforceable term also depends on maintenance-fee status and any terminal disclaimer.
The practical exclusivity timeline is:
| Event |
Date or issue |
| US patent grant |
September 17, 2013 |
| Nominal term |
20 years from the applicable earliest nonprovisional filing date |
| Patent-term adjustment |
Must be checked in USPTO records |
| Patent-term extension |
Not apparent from the claims; must be checked separately |
| Maintenance fees |
Must be checked at the USPTO |
| Expiration |
Cannot be established from claim text alone |
Are Paragraph IV challenges relevant?
Paragraph IV litigation is relevant only if the patent is listed in the Orange Book for a drug product and a generic applicant certifies that the listed patent is invalid, unenforceable or not infringed.[2]
Because the claims are directed to an inhaler manifold and dispenser, the more likely dispute pathways are:
- patent litigation involving an inhaler manufacturer;
- an ANDA dispute if the patent is listed for a specific drug-device product;
- a 505(b)(2) patent certification;
- declaratory-judgment litigation; or
- commercial licensing and supply agreements.
A generic dry-powder inhaler could face a Paragraph IV issue only if the relevant patent is properly listed against the reference product. The patent number alone does not establish that status.
What generic entry risks exist?
Generic entry risk depends on the architecture of the proposed inhaler.
| Generic design |
Exposure under US 8,534,281 |
| Single blister pocket and single powder inlet |
Generally lower exposure to claim 1 |
| Multiple blister pockets but separate airflow paths |
Potentially lower exposure if no common chimney and chamber exist |
| Multiple pockets with a common chamber but no bleed holes |
Strong design-around candidate |
| Multiple pockets with bypass holes that alter powder flow |
Material infringement risk |
| Same manifold geometry with different plastics |
High exposure because material is not required by claim 1 |
| Same geometry with different drug formulation |
High exposure; drug identity does not avoid device claims |
| Sequential rather than simultaneous pocket use |
Requires detailed comparison with the plural-pairing limitations |
| Separate manifold and mouthpiece components |
Claims 1 and 32 may remain relevant |
The most direct design-around is to eliminate one of the claim's structural combinations:
- use a separate airflow channel for each blister;
- use a single shared powder inlet without plural paired exits;
- mix the streams outside the claimed chamber;
- use a chamber without chimney-to-chamber bleed holes;
- use a different blister-opening and airflow interface; or
- deliver the drugs through separate inhalers.
Each design-around carries separate risks under other patent families.
Which claim limitations are most important in litigation?
The likely dispute points are:
"Plural pairings"
The patentee would likely argue that each chimney exit and chamber inlet must correspond to an individual opened pocket. The accused device may dispute whether the claimed pairings exist where airflow spreads through a common plenum.
"Side-by-side"
This limitation may distinguish an arrangement in which the chimney exit and chamber inlet are vertically separated, axially offset or connected through an intermediate duct.
"Bleed holes"
The holes must provide airflow between the chimney and chamber. General openings, leakage paths or downstream vents may not satisfy the limitation unless they perform the claimed connection and airflow function.
"Disruptively impact"
This is a functional limitation. Evidence may include airflow visualization, particle deposition testing, pressure measurements and computational modelling.
"Only a single chimney inlet"
A manifold with multiple external air inlets may avoid this limitation even if the downstream geometry is similar.
"Open blister pocket"
The patent is tied to powder extraction from an opened pocket. A capsule, reservoir or closed-pocket system may fall outside the literal claim scope.
What licensing deals and commercial relationships are relevant?
The claims identify a technology that is suitable for licensing to inhaler developers, device manufacturers and combination-product sponsors. The relevant commercial structure would normally involve:
- ownership of the manifold patent family;
- licenses to inhaler manufacturers;
- rights to associated blister-strip patents;
- rights to airflow and deagglomeration patents;
- manufacturing rights for moulded manifolds; and
- product-specific sublicenses.
The supplied information does not identify a licensee, settlement agreement or assignment chain. Those issues cannot be established from claim language.
A transaction review should separate:
- patent ownership;
- exclusive or nonexclusive device licenses;
- field-of-use restrictions;
- territory;
- royalty obligations;
- improvement rights;
- sublicensing rights; and
- obligations tied to FDA-approved products.
What geographic coverage does the patent provide?
US 8,534,281 provides protection only in the United States. International protection would depend on related applications in jurisdictions such as:
- Europe;
- United Kingdom;
- Canada;
- Australia;
- Japan;
- China; and
- other PCT national-phase countries.
A US patent does not create automatic rights in those jurisdictions. The international landscape should be reviewed family-by-family because claims, prosecution amendments, expiration dates and maintenance status may differ.
What is the overall patent strength?
The patent estate represented by US 8,534,281 is strongest against inhalers that combine:
- multiple blister packs;
- simultaneous powder extraction;
- a single common manifold;
- paired chimney exits and chamber inlets;
- bleed holes between chimney and chamber; and
- a common mouthpiece.
It is weaker against:
- single-dose or single-blister devices;
- capsule-based inhalers;
- devices with independent airflow channels;
- devices that mix powder outside the claimed chamber;
- systems with no bleed holes; and
- architectures using a separate mixing chamber unrelated to the blister interface.
The claims create substantial design-around pressure but do not block the full field of dry-powder inhalers.
Key Takeaways
- US 8,534,281 is a device patent focused on a multi-blister airflow manifold.
- Claim 1 requires a single chimney inlet, plural chimney exits, plural chamber inlets, side-by-side pairings and bleed holes connecting the chimney and chamber.
- Claims 2-4 and 24 emphasize a bleed airflow that is larger than the powder-entraining airflow.
- Claims 29 and 32 extend the core manifold protection to mouthpiece subassemblies and dispenser devices.
- Claims 43-45 and 50-51 cover inhaler systems capable of delivering bronchodilator and anti-inflammatory therapies, but do not claim a specific drug composition.
- The patent is not, based on the supplied claims, a conventional active-ingredient or formulation patent.
- Orange Book relevance depends on whether the patent was listed against a specific approved drug product.
- The strongest design-arounds remove the common chimney-chamber architecture or eliminate the bleed-hole airflow path.
- Patent expiration cannot be calculated reliably from the grant date or claim text alone.
- Generic and 505(b)(2) exposure depends on both Orange Book listing status and the architecture of the proposed inhaler.
FAQs
Does US 8,534,281 cover a single-strip blister inhaler?
Potentially, but claim 1 requires plural chimney exits, plural chamber inlets and plural pairings associated with opened blister pockets. A single-strip device using only one active powder path may not satisfy those limitations.
Can changing the inhaler plastic avoid infringement?
Usually not if the accused device otherwise satisfies claim 1. Claims 19-21 address particular materials, but claim 1 does not require HDPE or a fluoropolymer.
Does using different drugs avoid the patent?
No. The core claims are directed to the manifold and dispenser architecture. Changing the active ingredients does not avoid infringement if the device still meets the structural and functional limitations.
Are bleed holes required to be physically separate from the chimney exits?
Claim 1 requires one or more bleed holes between the chimney and chamber. Claims 16-18 and 55-61 add spacing, direction and geometry requirements, but the independent claim does not specify one universal bleed-hole shape or distance.
Can a competitor avoid the patent by delivering the two medicines sequentially?
Possibly, if the sequential device lacks the plural simultaneous pairings and associated airflow structure required by claim 1. Sequential operation alone does not resolve infringement without comparing the actual manifold geometry.
References
- United States Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation guidance. https://www.uspto.gov/patents/laws/patent-term-adjustment
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book
- U.S. Food and Drug Administration. (2024). 21 C.F.R. § 314.53: Submission of patent information. https://www.ecfr.gov/current/title-21/section-314.53
- United States Patent and Trademark Office. (2013). U.S. Patent No. 8,534,281, Manifold for use in a medicament dispenser device. https://patents.google.com/patent/US8534281B2/en
